Icariin Alleviates Diabetes‐Associated Cognitive Dysfunction Through Modulation of LCN2–MEK/ERK Signaling‐Associated Neuroinflammation
Icariin lindert diabetesassoziierte kognitive Dysfunktion durch Modulation der mit Neuroinflammation assoziierten LCN2–MEK/ERK-Signalgebung
CNS Neuroscience & Therapeutics · 2026-07 · 32 (7)
DOI: 10.1002/cns.71008 ↗Auf einen Blick
In Maus- und Zellmodellen verbesserte Icariin die durch Diabetes bedingte kognitive Dysfunktion. Gleichzeitig nahmen hippocampale Neuroinflammation und die Aktivierung von LCN2–MEK/ERK ab.
Fragestellung
Welche Wirkung hat Icariin bei diabetesassoziierter kognitiver Dysfunktion und über welchen Mechanismus?
Methode
Proteomik und ELISA bei DACD- und DM-noCD-Patient:innen; zusätzlich db/db-Mäuse mit oraler Icariin-Gabe für 4 Wochen und HT22-Zellen unter Glukosestimulation.
Ergebnisse
Icariin verbesserte bei db/db-Mäusen räumliches Lernen und Gedächtnis. Es senkte hippocampale LCN2-Expression, hemmte die Phosphorylierung von MEK/ERK und verringerte entzündliche Reaktionen in HT22-Zellen.
Schlussfolgerung der Autor:innen
Die Studie legt nahe, dass Icariin DACD durch Angriff auf die LCN2–MEK/ERK-Signalgebung und durch Abschwächung der Neuroinflammation verbessert.
Kernaussagen
- Icariin verbesserte räumliches Lernen und Gedächtnis bei db/db-Mäusen
- Hippocampale Neuroinflammation und LCN2-Expression nahmen ab
- Der Effekt auf MEK/ERK war von LCN2 abhängig
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 06.07.2026. Verfasst von Xinyi Jiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College…. Hauptthemen laut MEDLINE: Flavonoids, Neuroinflammatory Diseases, MAP Kinase Signaling System, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Diabetes‐associated cognitive dysfunction (DACD) is a severe neurological complication of diabetes, yet effective preventive or therapeutic strategies remain limited. Icariin (ICA), a dietary‐derived natural flavonoid, has suggested potential neuroprotective properties in other diseases. However, its specific effects and underlying mechanisms in DACD are not fully elucidated. This study aimed to investigate the protective effects of ICA in DACD and to clarify its multi‐target mechanisms involving neuroinflammatory signaling.
Methods
We explored the differentially expressed proteins between DACD and diabetes mellitus without cognitive dysfunction (DM‐noCD) patients through proteomics and validated them by ELISA. We adopted an integrated research strategy combining in vivo and in vitro experiments. In vivo, db/db diabetic mice were orally administered ICA for 4 weeks. Cognitive function was evaluated using behavioral tests, hippocampal neuroinflammation was assessed by immunofluorescence and measurement of inflammatory cytokine levels, and the regulatory effect of ICA on the LCN2‐MEK/ERK signaling pathway was evaluated through molecular biological methods. In vitro, high glucose‐stimulated HT22 hippocampal neuronal cells were utilized to validate the role of the key LCN2‐MEK/ERK pathway via LCN2 knockdown experiments.
Results
ICA treatment significantly improved spatial learning and memory deficits in db/db mice. It alleviated hippocampal neuroinflammation, significantly downregulated hippocampal LCN2 expression, and inhibited phosphorylation of the MEK/ERK pathway. In HT22 cells, high glucose stimulation increased LCN2 expression and activated the MEK/ERK pathway, exacerbating inflammatory responses; ICA treatment counteracted these effects. Moreover, LCN2 knockdown suppressed MEK/ERK pathway activation, and ICA treatment induced no further changes under these conditions, suggesting that the inhibitory effect of ICA on this pathway is dependent on the presence of LCN2.
Conclusion
This study suggests that ICA ameliorates DACD by targeting the LCN2‐MEK/ERK signaling pathway while alleviating neuroinflammation. These findings highlight the protective effects of ICA on DACD and its potential in other neurodegenerative disorders that may be associated with metabolic dysregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
ORCID-Profile: Xinyi Jiao, Guoqing Tian
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jiao, X., Ren, Y., Yu, Z., Zhou, J., Wang, D., Yan, B., & Tian, G. (2026). Icariin Alleviates Diabetes‐Associated Cognitive Dysfunction Through Modulation of LCN2–MEK/ERK Signaling‐Associated Neuroinflammation. CNS Neuroscience & Therapeutics, 32(7). https://doi.org/10.1002/cns.71008
Vancouver
Jiao X, Ren Y, Yu Z, Zhou J, Wang D, Yan B, et al. Icariin Alleviates Diabetes‐Associated Cognitive Dysfunction Through Modulation of LCN2–MEK/ERK Signaling‐Associated Neuroinflammation. CNS Neuroscience & Therapeutics. 2026;32(7). doi:10.1002/cns.71008
BibTeX
@article{Jiao2026,
author = {Jiao, Xinyi and Ren, Yutong and Yu, Ziman and Zhou, Junxiong and Wang, Danyang and Yan, Bin and Tian, Guoqing},
title = {Icariin Alleviates Diabetes‐Associated Cognitive Dysfunction Through Modulation of LCN2–MEK/ERK Signaling‐Associated Neuroinflammation},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {7},
doi = {10.1002/cns.71008}
}
EUVIMED